FDA approves first biologic treatment for sepsis.
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D018805:Sepsis / Q000628:therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated